References
- Bracco F, Battaglia A, Chouza C et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs18(11), 733–746 (2004).
- Oertel W, Wolters E, Sampaio C et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov. Disord.21(3), 343–353 (2006).
- Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA284(15), 1931–1938 (2000).
- Holloway R, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol.61(7), 1044–1053 (2004).
- Rascol O, Brooks D, Korczyn A, De Deyn P, Clarke C, Lang A. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med.342(20), 1484–1491 (2000).
- Fahn S, Elton R. The Unified Parkinson’s Disease Rating Scale. In: Recent Developments in Parkinson’s Disease Volume 2. Fahn S, Marsden CD, Caine BD, Goldstein M (Eds). Macmillan Healthcare Information, NJ, USA, 153–163, 293–304 (1987).
- Stowe R, Ives N, Clarke C et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst. Rev.2, CD006564 (2008).
- Horstink M, Tolosa E, Bonuccelli U et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson’s disease. Eur. J. Neurol.13(11), 1186–1202 (2006).
- Miyasaki J, Martin W, Suchowersky O, Weiner W, Lang A. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology58(1), 11–17 (2002).
- Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J. Neural Transm.110(10), 1119–1127 (2003).
- Kohno Y, Takeuchi S. [Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole]. Nippon Yakurigaku Zasshi123(6), 429–440 (2004).
- Wynalda M, Wienkers L. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab. Dispos.25(10), 1211–1214 (1997).
- Jenner P, Könen-Bergmann M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin. Ther.31(11), 2698–2711 (2009).
- Hauser RA, Schapira AH, Rascol O et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov. Disord.25(15), 2542–2549 (2010).
- Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology17(5), 427–442 (1967).
- Schrag A, Spottke A, Quinn N, Dodel R. Comparative responsiveness of Parkinson’s disease scales to change over time. Mov. Disord.24(6), 813–818 (2009).
- Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. NIH, MD, USA (1976)
- Schapira A, Barone P, Hauser R et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson’s disease. In: Proceedings of the 13th Annual International Congress of Parkinson’s Disease and Movement Disorders. Poster WE-199 (2009).
- Rascol O, Barone P, Hauser RA et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson’s disease. Mov. Disord.25(14), 2326–2332 (2010).
- Leopold N, Polansky M, Hurka M. Drug adherence in Parkinson’s disease. Mov. Disord.19(5), 513–517 (2004).
- Grosset D, Antonini A, Canesi M et al. Adherence to antiparkinson medication in a multicenter European study. Mov. Disord.24(6), 826–832 (2009).
- Grosset K, Bone I, Grosset D. Suboptimal medication adherence in Parkinson’s disease. Mov. Disord.20(11), 1502–1507 (2005).
- Claxton A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23(8), 1296–1310 (2001).
- Nyholm D, Askmark H, Gomes-Trolin C et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin. Neuropharmacol.26(3), 156–163 (2003).
- Goetz C, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov. Disord.20(5), 523–539 (2005).
- Valldeoriola F, Cámara A. [Intraduodenal infusion of levodopa]. Rev. Neurol.51(1), 41–48 (2010).
- Reichmann H. Transdermal delivery of dopamine receptor agonists. Parkinsonism Relat. Disord.15(Suppl. 4), S93–S96 (2009).
- Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol.8(10), 929–937 (2009).
Websites
- Assessment Report for Sifrol®. (European Medicines Agency) EMEA/703892/2009 www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000133/WC500049957.pdf
- Guidance for industry. Extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations (US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, September 1997) www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070239.pdf